Literature DB >> 30760566

Adaptation of an R5 Simian-Human Immunodeficiency Virus Encoding an HIV Clade A Envelope with or without Ablation of Adaptive Host Immunity: Differential Selection of Viral Mutants.

Mingkui Zhou1,2,3, Michael Humbert2,3, Muhammad M Mukhtar1,2,3, Hanna B Scinto1,4, Hemant K Vyas1,2,3, Samir K Lakhashe1,2,3, Siddappa N Byrareddy2,3, Gregor Maurer1,5, Swati Thorat2,3, Joshua Owuor1, Zhao Lai6, Yidong Chen6,7, Anthony Griffiths1, Agnès-Laurence Chenine2,3,8,9, Sanjeev Gumber10,11, François Villinger10,11, David Montefiori12, Ruth M Ruprecht13,14,2,3,4.   

Abstract

Simian-human immunodeficiency virus (SHIV) infection in rhesus macaques (RMs) resembles human immunodeficiency virus type 1 (HIV-1) infection in humans and serves as a tool to evaluate candidate AIDS vaccines. HIV-1 clade A (HIV-A) predominates in parts of Africa. We constructed an R5 clade A SHIV (SHIV-A; strain SHIV-KNH1144) carrying env from a Kenyan HIV-A. SHIV-A underwent rapid serial passage through six RMs. To allow unbridled replication without adaptive immunity, we simultaneously ablated CD8+ and B cells with cytotoxic monoclonal antibodies in the next RM, resulting in extremely high viremia and CD4+ T-cell loss. Infected blood was then transferred into two non-immune-depleted RMs, where progeny SHIV-A showed increased replicative capacity and caused AIDS. We reisolated SHIV-KNH1144p4, which was replication competent in peripheral blood mononuclear cells (PBMC) of all RMs tested. Next-generation sequencing of early- and late-passage SHIV-A strains identified mutations that arose due to "fitness" virus optimization in the former and mutations exhibiting signatures typical for adaptive host immunity in the latter. "Fitness" mutations are best described as mutations that allow for better fit of the HIV-A Env with SIV-derived virion building blocks or host proteins and mutations in noncoding regions that accelerate virus replication, all of which result in the outgrowth of virus variants in the absence of adaptive T-cell and antibody-mediated host immunity.IMPORTANCE In this study, we constructed a simian-human immunodeficiency virus carrying an R5 Kenyan HIV-1 clade A env (SHIV-A). To bypass host immunity, SHIV-A was rapidly passaged in naive macaques or animals depleted of both CD8+ and B cells. Next-generation sequencing identified different mutations that resulted from optimization of viral replicative fitness either in the absence of adaptive immunity or due to pressure from adaptive immune responses.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  HIV; SHIV; SHIV-A; adaptation; immunodepletion; rhesus macaques

Mesh:

Substances:

Year:  2019        PMID: 30760566      PMCID: PMC6475780          DOI: 10.1128/JVI.02267-18

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  51 in total

1.  Simultaneous introduction of HIV type 1 subtype A and B viruses into injecting drug users in southern Ukraine at the beginning of the epidemic in the former Soviet Union.

Authors:  Alexey A Nabatov; Olga N Kravchenko; Maria G Lyulchuk; Alla M Shcherbinskaya; Vladimir V Lukashov
Journal:  AIDS Res Hum Retroviruses       Date:  2002-08-10       Impact factor: 2.205

2.  Species tropism of chimeric SHIV clones containing HIV-1 subtype-A and subtype-E envelope genes.

Authors:  Sunee Himathongkham; Gordon C Douglas; Adrienne Fang; Emily Yu; Susan W Barnett; Paul A Luciw
Journal:  Virology       Date:  2002-07-05       Impact factor: 3.616

3.  The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.

Authors:  Nanette Van Damme; Daniel Goff; Chris Katsura; Rebecca L Jorgenson; Richard Mitchell; Marc C Johnson; Edward B Stephens; John Guatelli
Journal:  Cell Host Microbe       Date:  2008-03-13       Impact factor: 21.023

4.  Monoclonal antibodies to the C4 region of human immunodeficiency virus type 1 gp120: use in topological analysis of a CD4 binding site.

Authors:  J A McKeating; J P Moore; M Ferguson; H S Marsden; S Graham; J W Almond; D J Evans; R A Weiss
Journal:  AIDS Res Hum Retroviruses       Date:  1992-04       Impact factor: 2.205

5.  Selection of unadapted, pathogenic SHIVs encoding newly transmitted HIV-1 envelope proteins.

Authors:  Gregory Q Del Prete; Braiden Ailers; Brian Moldt; Brandon F Keele; Jacob D Estes; Anthony Rodriguez; Marissa Sampias; Kelli Oswald; Randy Fast; Charles M Trubey; Elena Chertova; Jeremy Smedley; Celia C LaBranche; David C Montefiori; Dennis R Burton; George M Shaw; Marty Markowitz; Michael Piatak; Vineet N KewalRamani; Paul D Bieniasz; Jeffrey D Lifson; Theodora Hatziioannou
Journal:  Cell Host Microbe       Date:  2014-09-10       Impact factor: 21.023

6.  Global trends in molecular epidemiology of HIV-1 during 2000-2007.

Authors:  Joris Hemelaar; Eleanor Gouws; Peter D Ghys; Saladin Osmanov
Journal:  AIDS       Date:  2011-03-13       Impact factor: 4.177

7.  International technology transfer of a GCLP-compliant HIV-1 neutralizing antibody assay for human clinical trials.

Authors:  Daniel A Ozaki; Hongmei Gao; Christopher A Todd; Kelli M Greene; David C Montefiori; Marcella Sarzotti-Kelsoe
Journal:  PLoS One       Date:  2012-01-27       Impact factor: 3.240

8.  Fast and accurate short read alignment with Burrows-Wheeler transform.

Authors:  Heng Li; Richard Durbin
Journal:  Bioinformatics       Date:  2009-05-18       Impact factor: 6.937

9.  Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission.

Authors:  Jennifer D Watkins; Anton M Sholukh; Muhammad M Mukhtar; Nagadenahalli B Siddappa; Samir K Lakhashe; Mikyung Kim; Ellis L Reinherz; Sandeep Gupta; Donald N Forthal; Quentin J Sattentau; Francois Villinger; Davide Corti; Ruth M Ruprecht
Journal:  AIDS       Date:  2013-06-01       Impact factor: 4.177

Review 10.  C-terminal tail of human immunodeficiency virus gp41: functionally rich and structurally enigmatic.

Authors:  Jonathan D Steckbeck; Anne-Sophie Kuhlmann; Ronald C Montelaro
Journal:  J Gen Virol       Date:  2012-10-17       Impact factor: 3.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.